NextCure, Inc. (NASDAQ:NXTC) Given Average Rating of “Buy” by Brokerages

Shares of NextCure, Inc. (NASDAQ:NXTCGet Rating) have been assigned a consensus recommendation of “Buy” from the six brokerages that are covering the stock, reports. Two analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $15.00.

Several equities research analysts recently issued reports on the company. Piper Sandler decreased their price target on NextCure from $21.00 to $13.00 and set an “overweight” rating for the company in a report on Monday. Zacks Investment Research lowered NextCure from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, LADENBURG THALM/SH SH initiated coverage on NextCure in a research report on Tuesday, March 1st. They set a “buy” rating and a $16.00 price objective on the stock.

Several institutional investors have recently bought and sold shares of NXTC. JPMorgan Chase & Co. grew its holdings in NextCure by 257.4% during the 4th quarter. JPMorgan Chase & Co. now owns 8,774 shares of the company’s stock valued at $53,000 after buying an additional 6,319 shares in the last quarter. UBS Group AG lifted its position in NextCure by 224.6% in the first quarter. UBS Group AG now owns 9,160 shares of the company’s stock worth $45,000 after buying an additional 6,338 shares during the last quarter. Charles Schwab Investment Management Inc. bought a new stake in NextCure in the fourth quarter worth $60,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in NextCure in the third quarter worth $99,000. Finally, Jane Street Group LLC bought a new stake in shares of NextCure during the first quarter worth $73,000. 51.83% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ NXTC traded down $0.02 during midday trading on Friday, hitting $3.52. 1,738 shares of the stock traded hands, compared to its average volume of 135,058. The company has a market cap of $97.67 million, a PE ratio of -1.33 and a beta of 0.15. NextCure has a one year low of $3.25 and a one year high of $9.18. The business has a 50 day moving average price of $4.51 and a two-hundred day moving average price of $5.24.

NextCure (NASDAQ:NXTCGet Rating) last released its quarterly earnings data on Thursday, May 5th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.07). Research analysts predict that NextCure will post -2.68 earnings per share for the current fiscal year.

NextCure Company Profile (Get Rating)

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors.

See Also

Analyst Recommendations for NextCure (NASDAQ:NXTC)

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with's FREE daily email newsletter.